Developer docs
API playgroundTry for free, no card

Search company profiles

tilray germany

Full company profile

uuid02ma3lm

Namestring
tilray germany
Legal namestring
Tilray Deutschland GmbH
Company typeenum
Private
Founded yearint
2017
Descriptiontext

Tilray Deutschland GmbH is a wholly-owned German subsidiary of Tilray Brands, Inc. (Nasdaq: TLRY; TSX: TLRY), established in October 2017 and headquartered in Densborn, Germany. The company manufactures and distributes prescription-grade medical cannabis products — primarily dried cannabis flowers (Cannabisblüten) in multiple cultivars and full-spectrum cannabis extracts (Vollspektrum-Cannabisextrakte) produced via ethanol extraction and standardized with carrier oil for precise THC/CBD concentrations. Manufacturing is anchored in EU-GMP certified facilities in Germany (Neumünster), Portugal, and Canada, with cultivation based on clonal propagation from mother plants to ensure batch-to-batch consistency.

The business operates on a regulated pharmaceutical prescription model: physicians prescribe, pharmacies dispense and compound (Rezepturherstellung), and statutory health insurance (GKV) reimbursement is possible under conditions set by G-BA decisions. Tilray Germany holds import, wholesale, GDP, and narcotics trading authorizations and is listed with the five largest German pharmaceutical wholesalers. It also acts as a pharmaceutical entrepreneur (pharmazeutischer Unternehmer) exporting to 20 countries across five continents, including Luxembourg (government tender), the UK (via CC Pharma and Smartway Pharmaceuticals), Italy (via Tilray Medical Italia and Molteni Farmaceutici), the Czech Republic (Cansativa Group), and Malta. Customers span physicians, pharmacies, hospitals, government health programs, and end patients, with the company supporting 20+ clinical trials and observational studies globally. Go-to-market relies on a Competence Center, field sales representatives, healthcare professional education, conference participation, and the WE CARE digital information platform.

Short descriptiontext

Tilray Deutschland GmbH, a subsidiary of Tilray Brands, manufactures and distributes EU-GMP certified prescription medical cannabis flowers and full-spectrum extracts to physicians, pharmacies, and government health programs across 20 countries, with production facilities in Germany, Portugal, and Canada.

Operating statusenum
Operating
Ownership categoryenum
akta.pro rankint
HeadquartersDensborn, Germany
HQ citystring
Densborn
HQ countrystring
Germany
HQ regionstring
Europe
Markets served

Serves global market

Offices9 records

Each record includes

City, Country, Type, Description, Source

Keyword5 values
medical cannabis products, pharmaceutical cannabis manufacturing, cannabis flower cultivation, full-spectrum cannabis extracts, EU-GMP certified cannabis
Industry3 codes
PRIMARYCRANAFAI
Cannabis Dispensary + Pharmacy/Clinical Model (Patient Services)
Consumer Products & Retail/Tobacco, Alcohol & Cannabis Retail/Cannabis Dispensaries (Adult-Use & Medical)
SECONDARYCRANAFAB
Medical Cannabis Dispensaries
Consumer Products & Retail/Tobacco, Alcohol & Cannabis Retail/Cannabis Dispensaries (Adult-Use & Medical)
SECONDARYCRANAGAG
Medical Cannabis Delivery & Online Ordering
Consumer Products & Retail/Tobacco, Alcohol & Cannabis Retail/Cannabis Delivery & Online Ordering Retail
NAICS code3 codes
  • Medicinal and Botanical Manufacturing325411
  • Pharmaceutical Preparation Manufacturing325412
  • Drugs and Druggists' Sundries Merchant Wholesalers42421
SIC code3 codes
  • Pharmaceutical Preparations2834
  • Medicinal Chemicals & Botanical Products2833
  • Wholesale-Drugs, Proprietaries & Druggists' Sundries5122
Product category
Medical Cannabis (pharmaceutical-grade)
GTM motion2 records

Each record includes

Type, Description, Source

Revenue model1 record
1Prescription Medical Cannabis Products
TypeOne Time License
Description

Tilray Germany manufactures and distributes prescription pharmaceutical-grade cannabis products (dried flowers and full-spectrum extracts) to patients via pharmacies in Germany and for export to 20 countries. Products require a physician's prescription and are dispensed by pharmacies. The company also acts as pharmaceutical entrepreneur (pharmazeutischer Unternehmer) with import, wholesale, and narcotics trading permits.

tilraymedical.de
Marketing channels7 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels7 records

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components7 values
Supply Chain, Operations, Personnel, Marketing or Sales, Technology or R&D, Infrastructure, Others
GTM typeB2B
B2B
Offering typeHardware or Manufacturing
Hardware or Manufacturing
Core offering1 text field

Tilray Deutschland GmbH manufactures and supplies prescription medical cannabis products—dried cannabis flowers (Cannabisblüten) and full-spectrum cannabis extracts (Vollspektrum-Cannabisextrakte)—from EU-GMP certified facilities. Products are prescribed by physicians and dispensed through pharmacies, with the company also serving as a pharmaceutical entrepreneur holding import, wholesale, and narcotics trading permits. The portfolio supports individualized therapy through THC-dominant, CBD-dominant, and balanced THC/CBD formulations, complemented by a Competence Center providing prescribing, dosing, and reimbursement support to healthcare professionals.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 6 values shown
  • 400,000+ patients treated globally with Tilray medical cannabis products
+5 more records
Product overview1 text field

Tilray Germany operates as a medical cannabis manufacturer and supplier offering two core product lines: Cannabisblüten (dried cannabis flowers) in various cultivars (Indica, Sativa, Hybrid, CBD-rich) and Vollspektrum-Cannabisextrakte (full-spectrum cannabis extracts) via ethanol extraction. Products serve as prescription medicines for compounding in pharmacies. The portfolio includes THC-dominant, CBD-dominant, and balanced THC/CBD formulations. Supporting services include the Tilray® Cannabis-Ausweis patient ID card and Quick-ID rapid testing products. Products are manufactured in EU-GMP certified facilities in Germany, Portugal, and Canada, with distribution to 20+ countries.

Product and service1 record
1Cannabisblüten (Cannabis Flowers)
Scale indicator8 records

Each record includes

Type, Value, Description, Source

Partnership16 partners
Strategic tierCoreTypeChannel Partner/ Reseller/ DistributorAnnounced on2026-02-12
Description

CC Pharma (Tilray's European pharmaceutical trading subsidiary) entered into a strategic agreement with Smartway Pharmaceuticals, a leading UK pharmaceutical distribution group, to improve pharmaceutical product availability across the UK. The agreement leverages Smartway's established national distribution infrastructure and CC Pharma's European sourcing strength and GMP capabilities to accelerate access to medicines, improve supply security, and expand reach through established healthcare channels. This also anchors Tilray within the UK health system for its own medical cannabis products.

Strategic tierCoreTypeChannel Partner/ Reseller/ DistributorAnnounced on2026-01-22
Description

Tilray Medical Italia (formerly FL Group) partners with Molteni Farmaceutici, one of Italy's leading pharmaceutical companies with extensive experience supplying hospitals, physicians, and pharmacies throughout Italy. The partnership supports medical education, responsible prescribing, and improved patient access while maintaining the highest quality, safety, and compliance standards.

3GEINO (Grupo Español de Investigación en Neuro-Oncología)
Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2024-01-16
Description

Tilray Medical supports an independent clinical study conducted by the Spanish Neuro-Oncology Research Group (GEINO) and the Complutense University of Madrid investigating the efficacy of medical cannabis in treating glioblastomas. Tilray provides pharmaceutical-quality medical cannabis (THC/CBD 1:1) for the Phase I dose-escalation study involving 30 patients across eight specialized neuro-oncology clinics in Spain.

tilraymedical.de
Strategic tierMinorTypeStrategic or Co-development PartnerAnnounced on2023-05-01
Description

Tilray Medical partnered with the ONCOWELLNESS research community for oncology and patient care in Italy by supporting Italy's leading conference for cancer and patient care, accredited by the Italian Ministry of Health. The conference is led by Dr. Vittorio A. Guardamagna and brings together leading Italian physicians from orthopedics, geriatrics, anesthesiology, oncology, and palliative care.

Strategic tierCoreTypeChannel Partner/ Reseller/ DistributorAnnounced on2023-04-01
Description

Tilray Medical expanded its European presence in the Czech Republic through a new export and distribution partnership with Cansativa Group. The partnership distributes EU-GMP certified medical cannabis products through pharmacies and hospitals to support patient access to medical cannabis in the Czech Republic.

Strategic tierCoreTypeChannel Partner/ Reseller/ DistributorAnnounced on2020-12-01
Description

Tilray and Hormosan signed a cooperation agreement for the distribution of medical cannabis extracts in Germany. Hormosan supports the distribution and marketing of Tilray's medical cannabis extract products to physicians and pharmacies in the German market.

7DGS (Deutsche Gesellschaft für Schmerzmedizin) / PraxisRegister Schmerz
Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2019-03-07
Description

Tilray announced support for the non-interventional TIBS (TILRAY Beobachtungsstudie für Schmerz) study in cooperation with the German Pain Society (DGS). The study collected real-world data from 1,000 pain patients treated with cannabinoids over one year, using the existing structures of the DGS PraxisRegister Schmerz.

tilraymedical.de
Strategic tierMinorTypeStrategic or Co-development Partner
Description

Research partnership for clinical studies on chemotherapy-induced nausea and vomiting (CINV) and cannabinoids and driving fitness.

Strategic tierMinorTypeStrategic or Co-development Partner
Description

Research partnership for clinical studies on pediatric epilepsy / Dravet Syndrome.

10University of British Columbia, Canada
Strategic tierMinorTypeStrategic or Co-development Partner
Description

Research partnership for clinical studies on post-traumatic stress disorder (PTSD) and HIV/AIDS-related inflammation.

tilraymedical.de
Strategic tierMinorTypeStrategic or Co-development Partner
Description

Research partnership for clinical studies on chronic obstructive pulmonary disease (COPD) and HIV/AIDS-related inflammation.

Strategic tierMinorTypeStrategic or Co-development Partner
Description

Research partnership for glioblastoma study.

13New York University, USA
Strategic tierMinorTypeStrategic or Co-development Partner
Description

Research partnership for clinical studies on alcohol use disorder / PTSD.

tilraymedical.de
Strategic tierMinorTypeStrategic or Co-development Partner
Description

Research partnership for clinical studies on taxane-induced neuropathies and neuropathic pain.

15University of California San Diego (UCSD), USA
Strategic tierMinorTypeStrategic or Co-development Partner
Description

Research partnership for clinical studies on essential tremor.

tilraymedical.de
Strategic tierMinorTypeStrategic or Co-development Partner
Description

Research partnership for clinical studies on significant behavioral problems in children with intellectual disabilities.

Recent move13 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight5 records

Each record includes

Type, Description

Peers10 records
TypeDirect peer
Description

Global medical cannabis producer with EU-GMP operations in Germany and broader Europe. Directly competes with Tilray in the same pharmacy-channel, prescription-based German medical cannabis market.

TypeDirect peer
Description

Canadian-headquartered medical cannabis producer with EU-GMP certified German production (Aurora Nordic) and competing flower and extract products supplied through German pharmacies.

TypeDirect peer
Description

German medical cannabis producer with domestic cultivation and EU-GMP certification, selling flowers and extracts directly into the German pharmacy channel — a direct local competitor to Tilray Germany.

TypeDirect peer
Description

German medical cannabis company supplying EU-GMP cannabis flowers and extracts to pharmacies across Germany; competes directly with Tilray on product range and physician relationships.

TypeDirect peer
Description

German-based cannabis distributor and importer handling both Tilray-branded products and competing EU-GMP lines into German pharmacies — overlapping with Tilray across distribution and select proprietary products.

TypeBroad incumbent
Description

Major German generic and specialty pharma company that has entered the medical cannabis market with EU-GMP products distributed through German pharmacies, offering broader pharma leverage alongside Tilray's specialist model.

TypeBroad incumbent
Description

Global pharmaceutical company that has launched medical cannabis products in select European markets, leveraging established pharma manufacturing and distribution infrastructure to compete with Tilray in regulated European channels.

8Schwabe Group (Dr. Willmar Schwabe)
TypeBroad incumbent
Description

German plant-based pharmaceutical manufacturer that has expanded into cannabis-based prescription medicines, competing in overlapping indications where Tilray's full-spectrum extracts are positioned.

TypeDirect peer
Description

Canadian medical and recreational cannabis producer with EU-GMP exports into Germany and other European markets, offering similar flower and extract categories via pharmacy distribution.

TypeEmerging player
Description

German medical cannabis company with cultivation in Germany and products competing in the pharmacy channel; smaller scale than Tilray but represents an emerging EU-domestic alternative with overlapping products.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat5 records

Each record includes

Type, Details

Key risks5 records

Each record includes

Headline, Details, Source

Key highlights6 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Named customers7 records

Each record includes

Name, Industry, Type, Use case, Source, UUID

Segment5 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile4 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
No
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Feature4 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles6 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

Subsidiaries2 records

Each record includes

Name, Acquired on, Relationship type, Type, Business focus

Compliance2 records

Each record includes

Name, Class, Description

Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

tilray germany

Medical Cannabis (pharmaceutical-grade)tilraymedical.de

Tilray Deutschland GmbH, a subsidiary of Tilray Brands, manufactures and distributes EU-GMP certified prescription medical cannabis flowers and full-spectrum extracts to physicians, pharmacies, and government health programs across 20 countries, with production facilities in Germany, Portugal, and Canada.

What tilray germany does

Tilray Deutschland GmbH is a wholly-owned German subsidiary of Tilray Brands, Inc. (Nasdaq: TLRY; TSX: TLRY), established in October 2017 and headquartered in Densborn, Germany. The company manufactures and distributes prescription-grade medical cannabis products — primarily dried cannabis flowers (Cannabisblüten) in multiple cultivars and full-spectrum cannabis extracts (Vollspektrum-Cannabisextrakte) produced via ethanol extraction and standardized with carrier oil for precise THC/CBD concentrations. Manufacturing is anchored in EU-GMP certified facilities in Germany (Neumünster), Portugal, and Canada, with cultivation based on clonal propagation from mother plants to ensure batch-to-batch consistency.

The business operates on a regulated pharmaceutical prescription model: physicians prescribe, pharmacies dispense and compound (Rezepturherstellung), and statutory health insurance (GKV) reimbursement is possible under conditions set by G-BA decisions. Tilray Germany holds import, wholesale, GDP, and narcotics trading authorizations and is listed with the five largest German pharmaceutical wholesalers. It also acts as a pharmaceutical entrepreneur (pharmazeutischer Unternehmer) exporting to 20 countries across five continents, including Luxembourg (government tender), the UK (via CC Pharma and Smartway Pharmaceuticals), Italy (via Tilray Medical Italia and Molteni Farmaceutici), the Czech Republic (Cansativa Group), and Malta. Customers span physicians, pharmacies, hospitals, government health programs, and end patients, with the company supporting 20+ clinical trials and observational studies globally. Go-to-market relies on a Competence Center, field sales representatives, healthcare professional education, conference participation, and the WE CARE digital information platform.

tilray germany firmographics

Firmographics
Name
tilray germany
Legal name
Tilray Deutschland GmbH
Website
https://tilraymedical.de
Company type
Private
Founded year
2017
Operating status
Operating
Short description
Tilray Deutschland GmbH, a subsidiary of Tilray Brands, manufactures and distributes EU-GMP certified prescription medical cannabis flowers and full-spectrum extracts to physicians, pharmacies, and government health programs across 20 countries, with production facilities in Germany, Portugal, and Canada.
Ownership category
akta.pro rank

tilray germany industry classification

Industry
Product category
Medical Cannabis (pharmaceutical-grade)
NAICS
Medicinal and Botanical Manufacturing (325411), Pharmaceutical Preparation Manufacturing (325412), Drugs and Druggists' Sundries Merchant Wholesalers (42421)
SIC
Pharmaceutical Preparations (2834), Medicinal Chemicals & Botanical Products (2833), Wholesale-Drugs, Proprietaries & Druggists' Sundries (5122)
akta.pro industry
PRIMARYCRANAFAI
Cannabis Dispensary + Pharmacy/Clinical Model (Patient Services)
Consumer Products & Retail/Tobacco, Alcohol & Cannabis Retail/Cannabis Dispensaries (Adult-Use & Medical)
SECONDARYCRANAFAB
Medical Cannabis Dispensaries
Consumer Products & Retail/Tobacco, Alcohol & Cannabis Retail/Cannabis Dispensaries (Adult-Use & Medical)
SECONDARYCRANAGAG
Medical Cannabis Delivery & Online Ordering
Consumer Products & Retail/Tobacco, Alcohol & Cannabis Retail/Cannabis Delivery & Online Ordering Retail

Keywords

  • Medical cannabis products
  • Pharmaceutical cannabis manufacturing
  • Cannabis flower cultivation
  • Full-spectrum cannabis extracts
  • EU-GMP certified cannabis

Where tilray germany is headquartered

Location

Headquarters

HQ city
Densborn
HQ country
Germany
HQ region
Europe

Offices9 records

Markets served

tilray germany business model

Business model
GTM type
B2B
Offering type
Hardware or Manufacturing
Cost components
Supply Chain, Operations, Personnel, Marketing or Sales, Technology or R&D, Infrastructure, Others

Revenue model

  1. Prescription Medical Cannabis Products: Tilray Germany manufactures and distributes prescription pharmaceutical-grade cannabis products (dried flowers and full-spectrum extracts) to patients via pharmacies in Germany and for export to 20 countries. Products require a physician's prescription and are dispensed by pharmacies. The company also acts as pharmaceutical entrepreneur (pharmazeutischer Unternehmer) with import, wholesale, and narcotics trading permits.

Go-to-market motion2 records

Distribution channels7 records

Marketing channels7 records

tilray germany product offering

Product offering

Core offering

Tilray Deutschland GmbH manufactures and supplies prescription medical cannabis products—dried cannabis flowers (Cannabisblüten) and full-spectrum cannabis extracts (Vollspektrum-Cannabisextrakte)—from EU-GMP certified facilities. Products are prescribed by physicians and dispensed through pharmacies, with the company also serving as a pharmaceutical entrepreneur holding import, wholesale, and narcotics trading permits. The portfolio supports individualized therapy through THC-dominant, CBD-dominant, and balanced THC/CBD formulations, complemented by a Competence Center providing prescribing, dosing, and reimbursement support to healthcare professionals.

Product overview

Tilray Germany operates as a medical cannabis manufacturer and supplier offering two core product lines: Cannabisblüten (dried cannabis flowers) in various cultivars (Indica, Sativa, Hybrid, CBD-rich) and Vollspektrum-Cannabisextrakte (full-spectrum cannabis extracts) via ethanol extraction. Products serve as prescription medicines for compounding in pharmacies. The portfolio includes THC-dominant, CBD-dominant, and balanced THC/CBD formulations. Supporting services include the Tilray® Cannabis-Ausweis patient ID card and Quick-ID rapid testing products. Products are manufactured in EU-GMP certified facilities in Germany, Portugal, and Canada, with distribution to 20+ countries.

Differentiator

Problem solved

Functional benefit

Products and services

  • Cannabisblüten (Cannabis Flowers)

Quantifiable outcome

  • 400,000+ patients treated globally with Tilray medical cannabis products
  • +5 more outcomes

Companies that use tilray germany

Customer profile

Named customers7 records

Segments5 records

Ideal customer profiles4 records

tilray germany technology and API

Technology

Technology focussed No

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Feature4 records

tilray germany partnerships and signals

Strategic signal

Partnerships

16 partnerships are on record, tiered core and minor.

  • Smartway PharmaceuticalscoreChannel Partner/ Reseller/ Distributor · 12 February 2026CC Pharma (Tilray's European pharmaceutical trading subsidiary) entered into a strategic agreement with Smartway Pharmaceuticals, a leading UK pharmaceutical distribution group, to improve pharmaceutical product availability across the UK. The agreement leverages Smartway's established national distribution infrastructure and CC Pharma's European sourcing strength and GMP capabilities to accelerate access to medicines, improve supply security, and expand reach through established healthcare channels. This also anchors Tilray within the UK health system for its own medical cannabis products.
  • Molteni FarmaceuticicoreChannel Partner/ Reseller/ Distributor · 22 January 2026Tilray Medical Italia (formerly FL Group) partners with Molteni Farmaceutici, one of Italy's leading pharmaceutical companies with extensive experience supplying hospitals, physicians, and pharmacies throughout Italy. The partnership supports medical education, responsible prescribing, and improved patient access while maintaining the highest quality, safety, and compliance standards.
  • GEINO (Grupo Español de Investigación en Neuro-Oncología)coreStrategic or Co-development Partner · 16 January 2024Tilray Medical supports an independent clinical study conducted by the Spanish Neuro-Oncology Research Group (GEINO) and the Complutense University of Madrid investigating the efficacy of medical cannabis in treating glioblastomas. Tilray provides pharmaceutical-quality medical cannabis (THC/CBD 1:1) for the Phase I dose-escalation study involving 30 patients across eight specialized neuro-oncology clinics in Spain.
  • ONCOWELLNESS (Italy)minorStrategic or Co-development Partner · 1 May 2023Tilray Medical partnered with the ONCOWELLNESS research community for oncology and patient care in Italy by supporting Italy's leading conference for cancer and patient care, accredited by the Italian Ministry of Health. The conference is led by Dr. Vittorio A. Guardamagna and brings together leading Italian physicians from orthopedics, geriatrics, anesthesiology, oncology, and palliative care.
  • Cansativa GroupcoreChannel Partner/ Reseller/ Distributor · 1 April 2023Tilray Medical expanded its European presence in the Czech Republic through a new export and distribution partnership with Cansativa Group. The partnership distributes EU-GMP certified medical cannabis products through pharmacies and hospitals to support patient access to medical cannabis in the Czech Republic.
  • Hormosan PharmacoreChannel Partner/ Reseller/ Distributor · 1 December 2020Tilray and Hormosan signed a cooperation agreement for the distribution of medical cannabis extracts in Germany. Hormosan supports the distribution and marketing of Tilray's medical cannabis extract products to physicians and pharmacies in the German market.
  • DGS (Deutsche Gesellschaft für Schmerzmedizin) / PraxisRegister SchmerzcoreStrategic or Co-development Partner · 7 March 2019Tilray announced support for the non-interventional TIBS (TILRAY Beobachtungsstudie für Schmerz) study in cooperation with the German Pain Society (DGS). The study collected real-world data from 1,000 pain patients treated with cannabinoids over one year, using the existing structures of the DGS PraxisRegister Schmerz.
  • University of Sydney (Australia)minorStrategic or Co-development PartnerResearch partnership for clinical studies on chemotherapy-induced nausea and vomiting (CINV) and cannabinoids and driving fitness.
  • Sick Kids Hospital, Toronto, CanadaminorStrategic or Co-development PartnerResearch partnership for clinical studies on pediatric epilepsy / Dravet Syndrome.
  • University of British Columbia, CanadaminorStrategic or Co-development PartnerResearch partnership for clinical studies on post-traumatic stress disorder (PTSD) and HIV/AIDS-related inflammation.
  • McGill University, CanadaminorStrategic or Co-development PartnerResearch partnership for clinical studies on chronic obstructive pulmonary disease (COPD) and HIV/AIDS-related inflammation.
  • Complutense Universidad, SpainminorStrategic or Co-development PartnerResearch partnership for glioblastoma study.
  • New York University, USAminorStrategic or Co-development PartnerResearch partnership for clinical studies on alcohol use disorder / PTSD.
  • Columbia University, New York, USAminorStrategic or Co-development PartnerResearch partnership for clinical studies on taxane-induced neuropathies and neuropathic pain.
  • University of California San Diego (UCSD), USAminorStrategic or Co-development PartnerResearch partnership for clinical studies on essential tremor.
  • Murdoch Children's Research Center, AustraliaminorStrategic or Co-development PartnerResearch partnership for clinical studies on significant behavioral problems in children with intellectual disabilities.

Scale indicators8 records

Recent moves13 records

Expansion highlights5 records

tilray germany competitors and assessment

Company assessment

Direct peers

  • Canopy Growth Corporation: Global medical cannabis producer with EU-GMP operations in Germany and broader Europe. Directly competes with Tilray in the same pharmacy-channel, prescription-based German medical cannabis market.
  • Aurora Cannabis: Canadian-headquartered medical cannabis producer with EU-GMP certified German production (Aurora Nordic) and competing flower and extract products supplied through German pharmacies.
  • Demecan: German medical cannabis producer with domestic cultivation and EU-GMP certification, selling flowers and extracts directly into the German pharmacy channel — a direct local competitor to Tilray Germany.
  • Canify Clinics (formerly Cannamedical): German medical cannabis company supplying EU-GMP cannabis flowers and extracts to pharmacies across Germany; competes directly with Tilray on product range and physician relationships.
  • Cansativa Group: German-based cannabis distributor and importer handling both Tilray-branded products and competing EU-GMP lines into German pharmacies — overlapping with Tilray across distribution and select proprietary products.
  • Organigram Holdings: Canadian medical and recreational cannabis producer with EU-GMP exports into Germany and other European markets, offering similar flower and extract categories via pharmacy distribution.

Broad incumbents

  • Stada Arzneimittel: Major German generic and specialty pharma company that has entered the medical cannabis market with EU-GMP products distributed through German pharmacies, offering broader pharma leverage alongside Tilray's specialist model.
  • Dr. Reddy's Laboratories: Global pharmaceutical company that has launched medical cannabis products in select European markets, leveraging established pharma manufacturing and distribution infrastructure to compete with Tilray in regulated European channels.
  • Schwabe Group (Dr. Willmar Schwabe): German plant-based pharmaceutical manufacturer that has expanded into cannabis-based prescription medicines, competing in overlapping indications where Tilray's full-spectrum extracts are positioned.

Emerging players

  • Sanity Group (Sanatio Pharma / Vayamed): German medical cannabis company with cultivation in Germany and products competing in the pharmacy channel; smaller scale than Tilray but represents an emerging EU-domestic alternative with overlapping products.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks5 records

Key highlights6 records

Customer concentration

tilray germany social profiles

Digital presence

tilray germany compliance and trust

Trust signal

Compliance2 records

tilray germany financial estimates

Financial estimate

Revenue estimate

Valuation estimate

tilray germany leadership team

Management profile

Number of profiles

Profiles6 records

tilray germany subsidiaries and ownership

Company hierarchy

Subsidiaries2 records

tilray germany funding detail

Funding detail

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

tilray germany M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about tilray germany

What does tilray germany do?

Tilray Deutschland GmbH manufactures and supplies prescription medical cannabis products—dried cannabis flowers (Cannabisblüten) and full-spectrum cannabis extracts (Vollspektrum-Cannabisextrakte)—from EU-GMP certified facilities. Products are prescribed by physicians and dispensed through pharmacies, with the company also serving as a pharmaceutical entrepreneur holding import, wholesale, and narcotics trading permits. The portfolio supports individualized therapy through THC-dominant, CBD-dominant, and balanced THC/CBD formulations, complemented by a Competence Center providing prescribing, dosing, and reimbursement support to healthcare professionals.

Is tilray germany a public or private company?

tilray germany is a private company. It is classified as corporate owned and is currently operating.

When was tilray germany founded?

tilray germany was founded in 2017.

Where is tilray germany based?

tilray germany is headquartered in Densborn, Germany, in the Europe region.

How does tilray germany make money?

One revenue line is on record: prescription Medical Cannabis Products.

Who are tilray germany's main competitors?

Direct peers on record are Canopy Growth Corporation, Aurora Cannabis, Demecan, Canify Clinics (formerly Cannamedical), Cansativa Group and Organigram Holdings. Broad incumbents are Stada Arzneimittel, Dr. Reddy's Laboratories and Schwabe Group (Dr. Willmar Schwabe). Sanity Group (Sanatio Pharma / Vayamed) is listed as an emerging player.

Does tilray germany have an API?

No public API is recorded for tilray germany.

What industry is tilray germany in?

tilray germany's product category is Medical Cannabis (pharmaceutical-grade). Its primary akta.pro industry code is CRANAFAI, Cannabis Dispensary + Pharmacy/Clinical Model (Patient Services), with a secondary code of CRANAFAB, Medical Cannabis Dispensaries. Its NAICS code is 325411 and its SIC code is 2834.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales